ClinicalTrials.gg
TerminatedNCT05191706Updated Oct 5, 2026

Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

A Phase 4 interventional study of Dexamethasone and Prednisolone Acetate Ophthalmic in Cataract, sponsored by EyePoint Pharmaceuticals, Inc.. Terminated at 9 sites in United States. Open to participants aged Up to 3 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by EyePoint Pharmaceuticals, Inc. · Phase 4, Interventional, and Treatment

Why this study was terminated
EyePoint has submitted withdrawal of the NDA to the FDA for reasons unrelated to safety or efficacy

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 2 months ago, and no results have been posted to the registry.
Updated Oct 5, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
Up to 3 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing dexamethasone in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Dexamethasone · Cataract.

Enrollment
26th of 34
17 · median 50
Started
2022
with 5 others
Phase 4
18 of 34
none open now
Registered
24th of 34
by date
Lead sponsor
3 of 34
EyePoint Pharmaceuticals, Inc.

Among the 34 studies testing dexamethasone in Cataract, this one is the 26th largest by enrollment, is one of 6 that started in 2022, is one of 18 in phase 4, and was the 24th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

1 of the 34 studies testing dexamethasone in Cataract is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: Up to 3 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing dexamethasone in Cataract, or all of them as a file.
02

Study summary

A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

03

Conditions studied

  • Cataract

Browse trials for

Keywords

  • pediatric
  • cataract
04

Who can participate

Ages eligible
Up to 3 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing uncomplicated cataract surgery with or without a posterior chamber intraocular lens (IOL) implantation.
  • If a contact lens is used for correction of post-operative aphakia, it must be a silicone elastomer lens or a rigid gas permeable lens (no water content).
  • Other protocol-specified inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Presence of gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, respiratory, or other medical condition that could increase the risk to the subject as determined by the investigator.
  • Has a post-traumatic cataract.
  • Presence of active or suspected viral, bacterial, or fungal disease in the study eye.
  • Ocular hypertension with an IOP in the study eye >25 mmHg at Screening with or without treatment with anti-glaucoma monotherapy.
  • Subjects who have received a periocular injection in the study eye in the 3 months prior to Screening.
  • Subjects who have received any intravitreal corticosteroid delivery vehicle (eg, Retisert®, Ozurdex®, Iluvien®) in the study eye at any time.
  • Other protocol-specified exclusion criteria may apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    DEXYCU (dexamethasoneintraocular suspension) 9%

    A single 0.005-mL anterior chamber injection of DEXYCU (dexamethasoneintraocular suspension) 9%, equivalent to 517mcg dexamethasone.

    Drug: Dexamethasone

  • Active comparator
    Prednisolone acetate ophthalmic suspension (USP) 1%

    Active treatment control, prednisolone acetate ophthalmic suspension (USP) 1%, four times daily (QID) for 28days, followed by a treatment taper at the investigator's discretion.

    Drug: Prednisolone Acetate Ophthalmic

Interventions

  • single anterior chamber injection

  • DrugPrednisolone Acetate Ophthalmic

    topical administration four times a day for 28 days, followed by treatment taper

06

What researchers measure

Primary outcomes

  1. Grade of anterior chamber cells (ACC)

    Time frame: Post-Operative Day 14

Secondary outcomes

  1. Grade of anterior chamber flare (ACF)

    Time frame: Post-Operative Day 14

07

Study locations

9 sites
  • EyePoint Investigational Site
    Huntington Beach, California 92647, United States
  • EyePoint Investigational Site
    Palo Alto, California 94303, United States
  • EyePoint Investigative Site
    Boston, Massachusetts 02118, United States
  • EyePoint Investigational Site
    Jackson, Mississippi 39216, United States
  • EyePoint Investigational Site
    Omaha, Nebraska 68114, United States
  • EyePoint Investigational Site
    Buffalo, New York 14209, United States
  • EyePoint Investigative Site
    New York, New York 10032, United States
  • EyePoint Investigational Site
    Rochester, New York 14642, United States
  • EyePoint Investigational Site
    Charleston, South Carolina 29425, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2022 to primary completion in Aug 2025, 43 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Jan 2026 → Aug 2025 and completion Feb 2026 → Aug 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2021
First posted
Jan 13, 2022
StartActual
Jan 4, 2022
Primary completionActual
Aug 22, 2025was Jan 2026
CompletionActual
Aug 22, 2025was Feb 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated EyePoint has submitted withdrawal of the NDA to the FDA for reasons unrelated to safety or efficacy
changed Oct 5, 2026
Primary completion
Jan 2026→Aug 22, 2025 (actual)
Oct 5, 2026
Study completion
Feb 2026→Aug 22, 2025 (actual)
Oct 5, 2026
Enrollment
60 (estimated)→17 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Terminated
    Why stopped EyePoint has submitted withdrawal of the NDA to the FDA for reasons unrelated to safety or efficacy
    Primary completion Jan 2026→Aug 22, 2025 (now actual)
    Study completion Feb 2026→Aug 22, 2025 (now actual)
    Enrollment 60 (estimated)→17 (actual)
    + 6 other changes: verification date, registry dates, oversight details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05191706
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jan 13, 2022
Start date
Jan 4, 2022
Primary completion
Aug 22, 2025
Completion
Aug 22, 2025
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion